复发性小细胞肺癌的药物治疗现状及展望

Current status of pharmacotherapy for relapsed small cell lung cancer and its advances

虽然小细胞肺癌(SCLC)患者对一线化疗及放疗高度敏感,大部分患者仍在2年内复发并因全身转移而死亡。对于身体状况许可的SCLC复发患者,应接受二线及以上化疗。拓扑替康是惟一获得美国食品药品管理局批准用于SCLC二线治疗的药物;氨柔比星在日本获得批准。本文针对耐药问题,综述不同类型药物的联合应用,以及针对SCLC的生物靶向治疗药物的研发。

Despite being highly sensitive to first-line chemotherapy and radiotherapy treatments, most patients with small cell lung cancer （SCLC） still suffer from relapse within 2 years and die from systemic metastasis. If possible, relapsed SCLC patients should receive second or beyond second line chemotherapy. Topotecan is the first approved drug as second- line treatment for relapsed SCLC by FDA in USA. Amrubicin is a promising drug and has been approved in Japan. Many combinations of different chemotherapies are performed to overcome the chemo resistance, some of them are still in the clinical trials stage.